TMCnet News
Research and Markets: Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis ReportDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/kqfqgc/brain_cancer) has announced the addition of the "Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis" report to their offering. The new market research report titled Brain Cancer (Glioblastoma Multiforme): Disease and Pipeline Analysis, provides the biopharmaceutical industry with an in-depth overview of the current Glioblastoma Multiforme (GBM) market and an analysis of the significant opportunities that exist for effective new therapies. While GBM is the most common and most aggressive form of primary malignant brain tumor, it affects 240,000 patients globally each year, qualifying it as an orphan or rare disease, explained Andrew Shafer, President of ISR. Finding effective treatments for GBM offers pharmaceutical companies of all sizes a substantial opportunity. Currently there are only a few treatments, their impact on survival rate is minimal, and the orphan drug designation provides an extended patent exclusivity period. The report provides: - A thorough disease overview, including a discussion of symptoms, prognosis/ survival, incidence, and risk factors - Commercial rationale for drug manufacturers, including the lack of effective therapies, current treatment options, orphan disease status, and an active development field - Insight into trial, recruitment, regulatory, and pricing/ reimbursement environments for seven major and five emerging markets - An in-depth examination of both Early and Late Phase clinical development pipelines, R&D trends in the treatment of GBM, and recent late stage failures - A top-line analysis of on-going and recently completed GBM trials With this report, sponsors can identify how products in their pipeline could compete in this market, uncover strategic development opportunities, plan global clinical trial and market access strategies, and assess the competition with a full analysis of companies participating in this market, Schafer explained. Key Topics Covered: Chapter 1 - Disease Overview Chapter 2 - Commercial Rationale Chapter 3 - Environmental Analysis Chapter 4 - Clinical Development Pipeline Chapter 5. The Clinical Trial Environment For more information visit http://www.researchandmarkets.com/research/kqfqgc/brain_cancer |
